A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Initial Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Latest Information Update: 20 Dec 2024
At a glance
- Drugs BL-M07D1 (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
- 18 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
- 18 Dec 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2025.
- 13 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.